Alpha Tau Medical Ltd. DRTS

Alpha Tau completes patient enrollment in its multicenter IMPACT pancreatic cancer pilot study of Alpha DaRT following strong demand and multiple expansions. Enrollment completion advances Alpha Tau's pancreatic cancer clinical program but remains an early-stage pilot milestone.

Alpha Tau Medical Ltd. (DRTS) reported second quarter 2026 financial results and issued a corporate update. Quarterly results and updates deliver performance data that can shift near-term investor views without guaranteeing major strategic shifts.

Alpha Tau Medical (DRTS) shares fell 5.7% after the Alpha DaRT combo trial hit early-stop success on positive efficacy data. Early-stopped Alpha DaRT trial success advances regulatory path and commercialization timeline.

Alpha Tau Medical Ltd. (DRTS) reported 100% objective response rate and 18.2-month median overall survival using Alpha DaRT combined with pembrolizumab in locally advanced or metastatic head and neck cancer, exceeding the study's pre-specified success threshold. Strong efficacy data for lead product Alpha DaRT advances clinical validation and supports future regulatory and commercial prospects.

Alpha Tau Medical initiates first international Alpha DaRT treatment for brain cancer, testing platform expansion to new indications outside existing applications. First international brain cancer use expands Alpha DaRT platform to major new indication and geography.

Alpha Tau successfully treated first recurrent glioblastoma patient outside US with Alpha DaRT at Hadassah University Medical Center in Israel. First international Alpha DaRT glioblastoma treatment signals clinical expansion yet remains single-patient early milestone.

Alpha Tau Medical received FDA clearance to complete enrollment in the REGAIN recurrent glioblastoma trial and add two U.S. clinical sites. Early interim results showed 100% local disease control. FDA clearance plus 100% interim local control in glioblastoma trial marks major regulatory and clinical progress for Alpha Tau's core technology.

Alpha Tau Medical Ltd. (DRTS) shares jumped 22% after the company announced a $196.5M prostate cancer deal. $196.5M prostate cancer deal marks major strategic expansion with large revenue upside.

Alpha Tau Medical and Tolmar announced a strategic collaboration to introduce Alpha DaRT therapy to urological cancer patients in the United States. Partnership opens US market access for Alpha DaRT in urological cancers, representing major expansion step.

Alpha Tau Medical Ltd. (DRTS) presented strong overall survival results from Alpha DaRT® pancreatic cancer studies at the 2026 ASCO Annual Meeting. Positive survival data from pancreatic cancer trials at major oncology conference substantially strengthens development prospects and investor outlook.

Alpha Tau Medical prepares for multiple catalysts in 2026 centered on key data readouts from its ongoing cancer trials. Pivotal cancer trial data expected in 2026 can materially shift Alpha Tau Medical valuation and investor sentiment.

Alpha Tau Medical Ltd. (DRTS) announces groundbreaking interim results from U.S. Alpha DaRT® trial for recurrent glioblastoma: 100% local disease control, 67% complete response rate, favorable safety profile. Conference call scheduled for 8:30am ET. Groundbreaking interim trial results showing 100% local disease control and 67% complete response in recurrent glioblastoma represent a transformative breakthrough for Alpha Tau's oncology brachytherapy platform.

Alpha Tau Medical Ltd. (DRTS) announced early data from its REGAIN study, reporting two complete responses among glioblastoma patients treated with its Diffusing Alpha-emitters Radiation Therapy (DaRT) seeds. Two complete responses in an aggressive glioblastoma trial mark a major positive clinical milestone for DRTS's radiation therapy pipeline, likely boosting investor sentiment and development prospects.

Alpha Tau Medical Ltd. (DRTS) will host a conference call to discuss interim results from the first three patients treated for recurrent glioblastoma. Early interim clinical data from recurrent glioblastoma patients signals pipeline progress that could significantly boost investor sentiment and validate the company's radiation therapy platform.

Alpha Tau Medical Ltd. (DRTS) completed patient enrollment in its U.S. pivotal skin cancer study, advancing toward FDA approval of Alpha DaRT® for recurrent cutaneous squamous cell carcinoma. Completing enrollment in the pivotal U.S. study propels Alpha Tau toward FDA approval, significantly boosting commercialization prospects and investor sentiment.

Alpha Tau Medical Ltd. (DRTS) successfully treated the first pancreatic cancer patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute. First patient treatment in Italy advances international clinical expansion for Alpha DaRT in hard-to-treat pancreatic cancer.

Alpha Tau Medical Ltd. (DRTS) announces an upcoming podium presentation at the AHNS 12th International Conference on Head and Neck Cancer, showcasing study results of Alpha DaRT® combined with pembrolizumab for head and neck cancer treatment. Podium presentation of clinical study results at a major international conference on Alpha DaRT® with pembrolizumab signals significant clinical validation and potential market momentum.

Alpha Tau Medical Ltd. announces 100% local disease control rate and favorable safety profile in Alpha DaRT® pancreatic cancer trials, presented at DDW 2026. 100% local disease control in pancreatic cancer trials represents major clinical progress that could accelerate regulatory approval and enhance market positioning.

Alpha Tau Medical Ltd. (DRTS) announces presentation of combined results from three Alpha DaRT pancreatic cancer studies at the upcoming ASCO Annual Meeting. Presentation of combined data from three pancreatic cancer studies at the prestigious ASCO meeting signals significant clinical progress that could markedly enhance investor sentiment and company valuation.

Alpha Tau Medical Ltd. (DRTS) received FDA approval for an IDE supplement to expand the Alpha DaRT® IMPACT trial to pancreatic cancer patients receiving Gemcitabine with Abraxane® (Nab-Paclitaxel). FDA approval expands pivotal trial into high-need pancreatic cancer with standard chemotherapy, significantly advancing pipeline and boosting investor sentiment.

Alpha Tau Medical Ltd. (DRTS) successfully treated the first pancreatic cancer patient in Europe using Alpha DaRT® in the French multicenter ACAPELLA clinical trial. First European pancreatic cancer patient treatment with Alpha DaRT® marks key clinical trial milestone, enhancing international expansion and investor confidence.

Alpha Tau Medical Ltd. (DRTS) announces first-ever oral presentation of Alpha DaRT® pancreatic cancer data at Digestive Disease Week (DDW) 2026. First oral presentation of pancreatic cancer data at major conference boosts clinical validation, visibility, and investor sentiment significantly.

Alpha Tau Medical at conference announces Japan approval, rolling FDA PMA submission, and teases major 2026 data readouts. Japan approval, rolling FDA PMA, and pivotal 2026 data readouts represent major regulatory and clinical milestones boosting market access and investor confidence.

Alpha Tau Medical Ltd. (DRTS) announced full-year 2025 financial results and provided a corporate update. Full-year financial results and corporate update affect key financial performance and investor sentiment moderately.

H.C. Wainwright raised its price target for Alpha Tau Medical Ltd. (DRTS) to $12 from $9. H.C. Wainwright's 33% price target increase signals stronger analyst conviction, likely enhancing investor sentiment and driving short-to-medium term stock gains.

HekaBio and Alpha Tau Medical Ltd. (DRTS) secured regulatory approval in Japan for the Alpha DaRT treatment targeting solid tumors. Japanese approval enables market entry for Alpha DaRT, significantly expanding Alpha Tau Medical's international reach and growth potential.

Alpha Tau Medical Ltd. (DRTS) receives Japanese marketing approval for Alpha DaRT® therapy in unresectable locally advanced or locally recurrent head and neck cancer. Japanese marketing approval enables commercial entry into a major market for DRTS's lead radiation therapy product.

Alpha Tau Medical Ltd. has announced the initiation of five concurrent clinical trials in the U.S., aiming to advance its innovative cancer treatment technology. The company highlighted multiple significant milestones expected in the near future, which could enhance its market position and drive shareholder value. This strategic move is part of Alpha Tau's ongoing efforts to establish its presence in the oncology sector and improve patient outcomes. The initiation of multiple clinical trials represents a significant strategic move that could alter the company's trajectory and investor sentiment.

Alpha Tau Medical Ltd. (DRTS) has been identified as a strong sell stock due to concerns regarding its financial performance and market position. Analysts suggest that the company's recent developments may not align with investor expectations, leading to a negative outlook for its future. Investors are advised to reconsider their positions in light of these factors. Concerns about financial performance and market position indicate a significant impact on future performance and investor sentiment.

Alpha Tau Medical Ltd. (DRTS) is among the companies announced to present at the upcoming DealFlow Discovery Conference. The event aims to connect investors with innovative companies in various sectors, highlighting opportunities for investment and collaboration. Alpha Tau's participation underscores its commitment to engaging with potential investors and showcasing its advancements in cancer treatment technologies. Participation in the conference may enhance investor interest and visibility, but the overall impact on the company's trajectory is expected to be limited.